Brisbane, CA, April 27, 2020 – FlemingMartin is pleased to announce that MyoKardia (NASDAQ: MYOK), a biopharmaceutical company pioneering a precision approach to serious, neglected, and rare cardiovascular diseases, has hired Robert “Bob” Gatmaitan as Executive Director of Total Rewards.
Bob brings impressive financial, analytical, and technical skills to MyoKardia, along with strong management experience developed over more than 25 years in the total rewards function. Most recently, over the past 12 years, Bob created, developed and strengthened compensation programs, sales incentives, and equity programs across the globe for Sanofi Pasteur and Sanofi Genzyme (NASDAQ: SNY).
Before joining Sanofi, Bob managed compensation programs in the financial services and insurance industries with Lincoln Financial, ACE Group, and Cigna. He also consulted on a range of compensation-related issues, serving multinational corporations with the Hay Group. Bob earned his B.S. in Business Administration (majoring in Finance) from Drexel University in Philadelphia, PA.
MyoKardia (NASDAQ: MYOK) is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. Learn more at myokardia.com
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards and CEOs to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. Learn more at flemingmartin.com